MARKET OUTLOOK The primary goal of UC treatment is to induce and maintain remission with little to no clinical symptoms remaining. Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate patients, whereas IV and subcutaneous TNF-a inhibitors are primarily reserved for moderate to severe patients refractory to conventional treatment or for first-line treatment in the most severe patients. Lack of primary response or loss of response to TNF-a inhibitors is an ongoing concern; however, the IV-delivered CAM inhibitor Entyvio is a recent entry to the treatment armamentarium that offers an alternative mechanism of action for these patients, and has lead to increasing competition among the biologics.
QUESTIONS ANSWERED ·
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed ulcerative colitis patients?
- What are the quarterly trends in prescribing among recently-treated and new diagnosed ulcerative colitis patients?
- How has Enyvio been integrated into the treatment algorithm?
- What proportion of ulcerative colitis patients receive drug therapy within 365 days of diagnosis, and how quickly?
- What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of ulcerative colitis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with ulcerative colitis?
PRODUCT DESCRIPTION Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.